semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Myasthenia Gravis diagnosed as myasthenia gravis (MG) by clinical diagnosis QMG scores ≥7 at the time of enrollment basic treatment drugs are mainly glucocorticoids, and the efficacy of glucocorticoid therapy was not sufficient  receiving blood purification therapy or immunoglobulin therapy within 8 weeks before the study QMG swallowing function score ≥ 2 points or QMG vital capacity = 3 abnormal hepatic functions uncontrolled diabetes patients hyperkalemia patients immuno-inhibitors are forbidden due to malignancy, history of malignancy or history of HIV infection patients who are allergic to Tacrolimus or macrolide antibiotics receiving other immuno-inhibitors within 12 weeks
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Very Low Birth Weight Baby Pneumonia A cluster was eligible to participate if it Is located in Kintampo North or South Districts (this is the core study area for KHRC) Is primarily rural (in practice, this excludes Kintampo, which is a small city of approximately 40,000 people) Is operationally feasible (in practice, this excluded a handful very small, isolated clusters that would have presented extraordinary logistical challenges) Is home to women who primarily deliver at one of our four staffed birth facilities (in practice this excluded one village on the edge of the study area, in which women travel to another district for deliveries). A woman will be eligible to participate in the study if she Is in the first or second trimester of pregnancy (gestational age ≤ 24 weeks gestation; this is to ensure that the intervention is actually delivered prior to 27 weeks) Is carrying a live singleton fetus (twins will be excluded) Is the primary cook in her household or compound; and Is a non-smoker
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Fracture of Cervical Spine Fracture Dislocation of Cervical Spine The investigators will enroll consecutive alert, stable adults presenting to the study hospital EDs with potential c-spine injury after sustaining acute blunt trauma. These will be patients presenting with neck pain or with c-spine immobilization on an ambulance stretcher. Patient will be determined based on these at the time of arrival in the ED "Potential c-spine injury after sustaining acute blunt trauma" will patients with either: i) neck pain with any mechanism of injury (subjective complaint by the patient of any pain in the posterior aspect of the neck), and/or ii) presentation by ambulance with c-spine immobilization after injury (typically backboard and collar) "Alert" is defined as a Glasgow Coma Scale103 score of 15 (converses, fully oriented, and follows commands) "Stable" refers to normal vital signs as defined by the Revised Trauma Score31 (systolic blood pressure 90 mm Hg or greater and respiratory rate between 10 and 24 breaths per minute) "Acute" refers to injury within the past 48 hours  Patients under the age of 16 years Patients who do not satisfy the definition of "potential c-spine injury" as defined above (for example, patients with neither neck pain nor arriving with ambulance c-spine immobilization will be excluded) Patients with Glasgow Coma Scale score less than 15 Patients with unstable vital signs (systolic BP < 90; respiratory rate less than 10 or more than 24) Patients whose injury occurred more than 48 hours previously Patients with penetrating trauma from stabbing or gunshot wound Patients with acute paralysis (paraplegia, quadriplegia) Patients with known vertebral disease (ankylosing spondylitis, rheumatoid arthritis, spinal stenosis, or previous cervical spine surgery) Patients who return for reassessment of the same injury, or Patients referred from another hospital
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Neuroblastoma Patients must have histologically proven neuroblastoma and confirmation of refractory or recurrent disease with histologic confirmation at diagnosis or at the time of recurrence/progression Patients must be age > 12 months and ≤ 21 at initial diagnosis Life expectancy must be more than 3 months If measurable disease, this must be demonstrated by residual abnormal tissue at a primary or metastatic site measuring more than 1 cm in any dimension by standardized imaging (CT or MRI); tumor must be accessible for biopsy. Patients with bone marrow only disease expected to be > 75% are eligible to enroll Current disease state must be one for which there is currently no known curative therapy Lansky or KarnofskyScore must be more than 50 Patients without bone marrow metastases must have an ANC > 750/μl and platelet count > 50,000/μl Adequate liver function must be demonstrated, defined as Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age AND SGPT (ALT) < 10 x upper limit of normal (ULN) for age  Patients who have received any chemotherapy within the last 7 days prior to enrollment and 14 days prior to study treatment start date Patients who have received any radiotherapy within the last 30 days must have another site of disease to follow Patients receiving anti-tumor therapy for their disease or any investigational drug concurrently Patients with serious infection or a life-threatening illness (unrelated to tumor) that is > Grade 2 (NCI CTCAE V4.0), or active, serious infections requiring parenteral antibiotic therapy Patients with any other medical condition, including malabsorption syndromes, mental illness or substance abuse, deemed by the Investigator to be likely to interfere with the interpretation of the results or which would interfere with a patient's ability to sign or the legal guardian's ability to sign the informed consent, and patient's ability to cooperate and participate in the study
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 55.0-85.0,  Alzheimer's Disease age 55 to 85 years; 2. should have a mild-to-moderate AD diagnosis (MMSE 10-26 inclusive); 3. should have evidence of elevated cortical amyloid by PET using florbetapir F18 (Amyvid) [i.e. a positive scan], assessed qualitatively according to the Amyvid product label. 4. if on anti-dementia treatment should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or Memantine or Axona); 5. stable on all other medications for at least 30 days prior to screen; 6. should be fluent in English; 7. should be physically able to participate by medical history, clinical exam and tests; 8. should have a study partner to accompany them to scheduled visits  clinically relevant arrhythmias; 2. a resting pulse less than 50; 3. active cancer other than non-melanoma skin cancers; 4. use of another investigatory drug within 2 months of screening; 5. significant stroke or head trauma by history or MRI; 6. contraindication for having a MRI; 7. diagnostic and Statistical Manual of Mental Disorders-IV for a current major psychiatric disorder; 8. sensitivity to yeast or yeast products; 9. impaired kidney function as measured by a Glomerular Filtration Rate less than 60 milliliters/min; 10. preexisting fluid retention, pulmonary infiltrates, or congestive heart failure; 11. history of moderate-to-severe lung disease; 12. history of moderate-to-severe liver disease; 13. pregnant women, or any women who feel they are likely to become pregnant during the study; 14. prisoners
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 0.0-45.0,  Anemia, Sickle Cell Complex and Transfusion-dependent Hemoglobinopathies Thalassemia Diamond-Blackfan Anemia Bone Marrow Failure Syndromes Alpha-Thalassemia Beta-Thalassemia The following are established to identify subjects with hemoglobinopathies, hematologic or bone marrow failure syndromes who have a high predicted morbidity and are at risk for early mortality Patients with alpha or beta thalassemia major Patients with Diamond-Blackfan anemia and other bone marrow failure syndromes, characterized by severe chronic anemia Patients with other complex and transfusion-dependent hemoglobinopathies, including sickle cell disease Patients with sickle disease who have one or more of the following Overt or silent stroke Neurocognitive impairment Pain crises 2 or more episodes per year for past year One or more episodes of acute chest syndrome Osteonecrosis involving 1 or more joints  Patients with cirrhosis, extensive bridging hepatic fibrosis, or active hepatitis are excluded from enrollment Uncontrolled infection or severe concomitant diseases, which in the judgment of the Principal Investigator, indicate that the patient could not tolerate reduced intensity transplantation Severe impairment of functional performance as evidenced by a Karnofsky score <70% (patients ≥16 years old) or Lansky (children <16 years old) score <70% Renal insufficiency (GFR <50 ml/min/1.73 m2) Subjects with a positive human immunodeficiency virus (HIV) antibody test result Subjects who are pregnant, as indicated by a positive serum human chorionic gonadotrophin (HCG) test Subjects whose only donor is pregnant at the time of intended transplant Subjects of childbearing potential who are not practicing adequate contraception as defined by the investigator at the site Allogeneic hematopoietic stem cell transplant within the previous 1 year Subjects must not have had previous radiation therapy that would preclude total body irradiation (TBI) (as determined by a radiation therapist)
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 0.0-21.0,  Adenovirus Anesthesia Anxiety Anxiolysis Autism Autistic Disorder Bacterial Meningitis Bacterial Septicemia Benzodiazepine Bipolar Disorder Bone and Joint Infections Central Nervous System Infections Convulsions Cytomegalovirus Retinitis Early-onset Schizophrenia Spectrum Disorders Epilepsy General Anesthesia Gynecologic Infections Herpes Simplex Virus Infantile Hemangioma Infection Inflammation Inflammatory Conditions Intra-abdominal Infections Lower Respiratory Tract Infections Migraines Pain Pneumonia Schizophrenia Sedation Seizures Skeletal Muscle Spasms Skin and Skin-structure Infections Treatment-resistant Schizophrenia Urinary Tract Infections Withdrawal Sepsis Gram-negative Infection Bradycardia Cardiac Arrest Cardiac Arrhythmia Staphylococcal Infections Nosocomial Pneumonia Neuromuscular Blockade Methicillin Resistant Staphylococcus Aureus Endocarditis Neutropenia Headache Fibrinolytic Bleeding Pulmonary Arterial Hypertension CMV Retinitis Hypertension Chronic Kidney Diseases Hyperaldosteronism Hypokalemia Heart Failure Hemophilia Heavy Menstrual Bleeding Insomnia Children (< 21 years of age) who are receiving understudied drugs of interest per standard of care as prescribed by their treating caregiver  Failure to obtain consent/assent (as indicated) Known pregnancy as determined via interview or testing if available
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 30.0-70.0,  Diabetes Age ≥ 30 and ≤ 70 years balanced gender ratio (50: 50) BMI 20-25 kg/m² (normal weight subjects) BMI 25-35 kg/m² (obese subjects)  acute illness within the last 2 weeks before the examination autoimmune diseases and disorders immune compromised (leukocytes <5000/μl) renal insufficiency (creatinine> 1.5 mg / dl) heart disease, condition after heart attack anemia (Hb <12 g / l, controls at each examination), blood donation within 4 weeks before the examination participation in another study within 2 months before the examination wear a metal or magnetic objects on or in the body claustrophobia use of immunomodulatory drugs (cortisol, antihistamines, aspirin)
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Nervousness Life Experiences All Danish-speaking expected gynaecological cancer patients, who are offered open surgery at Odense University Hospital, who can speak for themselves and have the opportunity to have close relative to follow before anaesthesia and who accept participation  Senility
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 12.0-20.0,  HPV16 Anitbody Levels Post Vaccination HPV18 Antibody Levels Post Vaccination The following will be reviewed at the time of enrollment, and where noted, confirmed at the clinic visit, immediately prior to blood draw Subject is aged 12-17 years as of August 31, 2011 Subject received at least one dose of HPV vaccine, Cervarix (GSK, UK), from October 1, 2008 through October 31, 2009 as a part of the PATH HPV vaccine demonstration project in Nakasongola, Uganda Signed and dated informed written consent form (with both parent and subject s signatures) received (confirmed at clinic visit) Subject is afebrile, in good apparent health (confirmed at clinic visit) Subject assents to participate (confirmed at clinic visit) Subject is able to comply with the study protocol (confirmed at clinic visit) Subject plans to stay in Nakasongola for the duration of enrolment, which is expected to be about week between signed consent and blood draw  The following will be reviewed at the time of enrollment, and where noted, confirmed at the clinic visit Prior HPV vaccination outside the PATH HPV vaccine demonstration project period Subject is known to be pregnant or lactating at the time of the scheduled blood draw (confirmed at clinic visit) Subject has an apparent moderate or severe acute illness or has fever (confirmed at clinic visit) Clinical history of bleeding disorders such as haemophilia, thrombocytopenia, or anticoagulant therapy Investigational drug or investigational vaccine or licensed vaccine administered during the period from 30 days before the date of the scheduled blood draw (confirmed at clinic visit) Subject receives immunoglobulins and/or any blood products during the period from 30 days before the date of the scheduled blood draw (confirmed at clinic visit) Subject or subject s parents refused to sign written consent Subject does not assent at the time of the blood draw
Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Intrinsic Aging of Skin Solar Elastosis Male or female patients who meet all of the following are eligible for this study Eighteen years of age or older Moderate to severe lateral orbital rhytids at maximum smile (score of [2] or [3] by physician assessment) Negative pregnancy test for females of childbearing potential Time and ability to complete the study and comply with instructions Understanding of the study and contents of the informed consent  Patients who meet any of the following are not eligible for this study Previous treatment to the glabellar area, forehead or lateral orbital rhytids with Dysport® or Botox® Cosmetic or other botulinum toxin within 180 days of entry into the study. Botulinum toxin treatment of areas other than the lateral orbital rhytids at any time during the study Patients with an ongoing treatment-related AE from any Dysport® or Botox® Cosmetic or botulinum toxin study Inability to substantially lessen lateral orbital lines by physically spreading them apart Permanent or semi-permanent dermal fillers in the lateral orbital rhytids at any time Ablative skin resurfacing on the lateral orbital rhytids at any time preceding the study or planning to during the current study Upper eyelid blepharoplasty or brow lift at any time preceding the study or planning to during the current study Non-ablative treatments in the lateral orbital region for skin dyschromias (e.g. Intense Pulsed Light, light-emitting diodes) at any time during the current study Non-ablative dermal treatment in the lateral orbital area for skin tightening (e.g. radiofrequency treatments at any time preceding the current study or planned to have this done during the current study Retinoid, microdermabrasion, or prescription-level glycolic acid treatments to the lateral orbital area within 2 weeks prior to study participation or during the current study